News
In study MP4001, 49.1% of patients treated with Dymista achieved a clinically significant 50% improvement in rTNSS (Total Nasal Symptom Score).
Meda announced positive results from its Phase 3 trial of Dymista (azelastine HCl and fluticasone propionate) nasal spray in patients with seasonal allergic rhinitis. The randomized, double-blind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results